Humanigen

THE CYTOKINE STORM COMPANY

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of immunologic disorders including cancers and infectious diseases (COVID-19), by preventing and treating cytokine storm via its novel, anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) Ephrin type-A receptor 3 (EphA3) and monoclonal antibody neutralization molecules.

Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of: 1) cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions and 2) biinding to EphA3 receptors founf on many solid tumors.

PRODUCT PIPELINE

- **Lenzilumab demonstrated positive results in 520 patient Phase 3 clinical trial** for treatment of hospitalized patients with **COVID-19** pneumonia.
- The **ACTIV-5/BET-B** trial sponsored by **NIAID/NIH** has fully enrolled over **400 hopsitalized COVID-19** patients with CRP levels <150 mg/L
- Pending confirmatory results from ACTIV-5/BET-B, **Humanigen plans to amdend its EVA** to include these results
- **Humanigen anticipates** including ACTIV-5/BET-B-results in **filings with EMA and MHRA**
- Humanigen announced **positive data** in a Phase 1b study of lenzilumab in **diffuse large B-cell lymphoma** (DLBCL), with plans to initiate a potential registrational Phase 2 study in 2022
- Potential registrational trials for **acute GvHD** to be initiated in 2022
- Enrollment in **CMML** continues

Two other pipeline candidates are currently in development for solid tumors, inadequately controlled asthma and other eosinophilic diseases.

- **Ifabotuzumab (iFab)**: anti-EphA3 monoclonal antibody currently being evaluated in solid tumors
- **HGEN005**: anti-EMR1 monoclonal antibody to be evaluated in severe eosinophilic diseases

PARTNERSHIPS

- Manufacturing Ageement with **Calalent** for lenzilumab
- Clinical Trial Agreement with **NIAID** in COVID-19
- Exclusive worldwide license agreement with the **University of Zurich** in GvHD
- Clinical Trial Agreement with **IMPACT Group** for aGvHD
- Pre-clinicial Trial Agreement with **Olivia Newton John Cancer Center** for iFab ADC development
- Manufacturing agreement with **Chime Biologics** to to produce lenzilumab bulk drug substance and drug product

For more information contact Cameron Durrant: **cdurrant@humanigen.com**

TEAM

Humanigen, Inc. is led by a senior management team with extensive leadership experience in the biotechnology and pharmaceutical industries.

Chairman & CEO
Cameron Durrant, MD, MBA

Chief Scientific Officer
Dale Chappell, MD, MBA

CONTACT

Humanigen, Inc.
6900 Tavistock Lakes Blvd, Suite 400
Orlando, Florida, 32827, USA
650-243-3100

Investor and Public Relations
ir@humanigen.com

Business Development
Bob Atwill | batwill@humanigen.com

Twitter
@humanigen

LinkedIn
linkedin.com/company/humanigen-inc

Facebook
@Humanigen

Website
www.humanigen.com